For Patients and Caregivers

Help Patients Save on Single-Dose XOFLUZA

Eligible patients may pay as little as $30 (up to $60 off) with the XOFLUZA coupon*

Nearly half of all patients who used the XOFLUZA coupon paid just $30 for the medication.29
Download Coupon

Or have your patients text Rx to 96260.
Message and data rates apply.

XOFLUZA® (baloxavir marboxil) Coupon Page
XOFLUZA® (baloxavir marboxil) Coupon Page

For patients:

  1. By using this coupon, you acknowledge that you meet the eligibility criteria and will comply with the terms and conditions.
  2. Present this coupon to your pharmacy along with a valid prescription for XOFLUZA and
    • You will pay the first $30
    • Genentech will pay up to the next $60 depending on your insurance coverage. Any additional amounts due are your responsibility

If you have any questions, call 1-855-XOFLUZA.

For pharmacists:

  1. The processing information on this card can be repeatedly used for all your patients.
  2. When you apply this offer, you are certifying that the patient meets the eligibility criteria, and that you have not submitted and will not submit a claim for reimbursement under any state- or federally funded prescription insurance program for this prescription.
  3. For insured patients, process a coordination of benefits (COB/split bill) claim using the patient’s prescription insurance for the PRIMARY claim. Submit a SECONDARY claim using BIN 600428, PCN 0678​0000 and GROUP 06780172. For cash-paying or uninsured patients, submit a PRIMARY claim using BIN 600428, PCN 0678​0000, and GROUP 06780172. For help processing the coupon, please call 1-855-659-9767.

COUPON PROCESSING INFORMATION: 

RxBIN: 600428
Group: 06780172
PCN: 06780000
Member ID: CLAIM

*Patient eligibility/terms and conditions:

  1. This offer is valid for eligible patients receiving a prescription for XOFLUZA for an FDA-approved indication. The offer may be used by those with commercial/private insurance, uninsured patients or those choosing to pay cash. This offer may not be used for any other product.
  2. This offer may not be used by patients in conjunction with prescription insurance under Medicaid, Medicare, TRICARE or similar federal or state programs. This offer is not health insurance or a benefit plan.
  3. Offer only valid in the United States and U.S. Territories. This offer is not transferable and may not be combined with any other offer.
  4. Offer must be presented along with a valid prescription for XOFLUZA at the time of purchase.
  5. The patient must be 18 years or older to receive coupon benefits or a parent or guardian must redeem this offer on the patient’s behalf.
  6. May be used twice. Valid until September 30, 2023.
  7. Coupon program is void where prohibited by law and on the date an AB-rated generic equivalent for XOFLUZA becomes available.
  8. Genentech USA, Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice. It is a violation of federal law to buy, sell, or counterfeit this offer.

Genentech is currently honoring all XOFLUZA coupons until September 30, 2023, regardless of the expiration date printed on materials. Only 1 coupon may be used per script.

Indication

XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for:

  • Treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours and who are:
    • otherwise healthy adults and pediatric patients 5 years of age and older, OR
    • adults and pediatric patients 12 years of age and older who are at high risk of developing influenza-related complications
  • Post-exposure prophylaxis (PEP) of influenza in patients 5 years of age and older following contact with an individual who has influenza.

 

Limitations of Use
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

Important Safety Information

Contraindications
XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.

 

Warnings and Precautions

Hypersensitivity: Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA.  Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.
 

Increased Incidence of Treatment-Emergent Resistance in Patients Less Than 5 Years of Age: XOFLUZA is not indicated in patients less than 5 years of age due to increased incidence of treatment-emergent resistance in this age group. In clinical trials, the incidence of virus with treatment-emergent substitutions associated with reduced susceptibility to baloxavir (resistance) was higher in pediatric subjects younger than 5 years of age (43%, 36/83) than in pediatric subjects ≥5 years to <12 years of age (16%, 19/117) or subjects ≥12 years of age (7%, 60/842). The potential for transmission of resistant strains in the community has not been determined.
 

Risk of bacterial Infections: There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

Adverse Reactions

  • The most common adverse reactions (≥1%) in adult and adolescent patients (≥12 years of age) in clinical studies for acute uncomplicated influenza were diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).
  • The most frequently reported adverse reactions (≥5%) in pediatric patients (5 to <12 years of age) in clinical studies for acute uncomplicated influenza were vomiting (5%) and diarrhea (5%).
  • The safety profile reported in a clinical study for post-exposure prophylaxis was similar in pediatric patients ages 5 to <12 years old as that reported in adults and adolescents 12 years of age and older.

Drug Interactions

Polyvalent cations: Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).

 

Vaccines: The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and, thereby, decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.


For additional Important Safety Information, please see the XOFLUZA full Prescribing Information.

You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.